Author

L. Leopold

Observed name: L. H. Leopold

Observed institutions: Northwestern University, University of North Carolina at Chapel Hill, Mayo Clinic, The University of Texas MD Anderson Cancer Center, Baylor College of Medicine, SUNY Upstate Medical University, Medisch Spectrum Twente, University of Alabama at Birmingham, Massachusetts General Hospital, Virginia Oncology Associates, Fred Hutch Cancer Center, Russian Cancer Research Center NN Blokhin, Sarah Cannon, University Hospital Münster, Cancer Care Northwest, GlaxoSmithKline (United States), New York Oncology Hematology, City Clinical Oncology Center, Duke Medical Center, Rocky Mountain Cancer Centers, Willamette Valley Cancer Institute and Research Center, Georgia Cancer Specialists, Sudbury Regional Hospital, Rutgers Cancer Institute, Heinrich Heine University Düsseldorf, Case Western Reserve University, Institut Curie, Incyte (United States), McMaster University

OpenAlex ID: A5111153609

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer

2011 · G. Sonpavde, V. Matveev, et al. · Annals of Oncology · 146

Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037

2016 · T.C. Gangadhar, O. Hamid, et al. · Annals of Oncology · 58

A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract

2005 · C. Wülfing, J.-P. Machiels, et al. · Journal of Clinical Oncology · 56

An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

2005 · A. L. A. Fields, D. A. Rinaldi, et al. · Journal of Clinical Oncology · 48

511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma

2015 · G. Gibney, O. Hamid, et al. · European Journal of Cancer · 34

Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer

2005 · H. J. Ross, G. R. Blumenschein, et al. · Journal of Clinical Oncology · 27

An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with hormone refractory prostate cancer (HRPC)

2008 · G. R. MacVicar, T. M. Kuzel, et al. · Journal of Clinical Oncology · 22

Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia

2001 · Daniel J. DeAngelo, D. Russo, et al. · ORCA Online Research @Cardiff (Cardiff University) · 16

An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate-resistant prostate cancer (CRPC)

2009 · G. R. MacVicar, A. Greco, et al. · Journal of Clinical Oncology · 13

A phase I/II (P1/P2) study of AT-101 in combination with topotecan (T) in patients with relapsed or refractory small cell lung cancer (SCLC) after prior platinum-containing first-line chemotherapy

2009 · R. S. Heist, J. Fain, et al. · Journal of Clinical Oncology · 11

An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL)

2009 · E. Kingsley, D. Richards, et al. · Journal of Clinical Oncology · 10

Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer

2009 · B. Poiesz, J. Reeves, et al. · Journal of Clinical Oncology · 7

Interim analysis of a phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with cytarabine and daunorubicin to patients < 60 years old with untreated acute myeloid leukemia.

2002 · DJ De Angelo, Charles A. Schiffer, et al. · Blood · 7

Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers

2009 · M. N. Saleh, H. Pitot, et al. · Journal of Clinical Oncology · 6

New clinical data from the DeCidE1 trial: Results on DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with advanced recurrent epithelial ovarian cancer

2018 · O. Dorigo, A.M. Oza, et al. · Annals of Oncology · 4

Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC).

2011 · G. R. Pond, A. J. Armstrong, et al. · Journal of Clinical Oncology · 4

Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial

2014 · H. Hurwitz, N. Uppal, et al. · Annals of Oncology · 3

PDF

A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC)

2011 · G. Sonpavde, V. B. Matveev, et al. · Journal of Clinical Oncology · 3

76 Preliminary Report of a First-in-human, Open-label, Multicenter, Phase I Study of AT-406 (Debio 1143), an Oral Small Molecule Multi-IAP Inhibitor, in Solid Tumors and Lymphomas

2012 · H. Hurwitz, H. Pitot, et al. · European Journal of Cancer · 2

Small molecule pan-bcl-2 inhibitor AT-101 induces apoptosis in NSCLC by up-regulating noxa and enhances antitumor activity of docetaxel or targeted kinase inhibitors

2009 · P. Min, Y. Zhang, et al. · Journal of Clinical Oncology · 2

209 POSTER An open-label, multicenter, phase 1/2 study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer

2008 · G. MacVicar, F.A. Greco, et al. · European Journal of Cancer Supplements · 2

Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP).

2011 · M. T. Fleming, G. R. Pond, et al. · Journal of Clinical Oncology · 1

Analysis of a phase I pharmacokinetic (PK)/food effect study of AT-101 in patients with advanced solid tumors

2009 · H. C. Pitot, D. Mould, et al. · Journal of Clinical Oncology · 1

AT-101 or placebo (P) with docetaxel (D) in second-line NSCLC with gene signature biomarker development

2009 · N. Ready, A. Potti, et al. · Journal of Clinical Oncology · 1

Content Validity Of A Patient-Reported Outcome Instrument For Pancreatic Cancer

2015 · D.M. Turner-Bowker, J. Paty, et al. · Value in Health

Works count: 29

Citation count: 484

H-index: 10

I10-index: 11